NasdaqGS:ARQTBiotechs
Arcutis Biotherapeutics (ARQT) Could Be 28% Undervalued As Profit And Guidance Improve
Why Arcutis Biotherapeutics Stock Is Back In Focus
Arcutis Biotherapeutics (ARQT) is drawing attention after reporting second quarter revenue of $129.86 million, a shift to net income of $15.01 million, and higher full year net product sales guidance.
See our latest analysis for Arcutis Biotherapeutics.
At a share price of $26.54, Arcutis Biotherapeutics has a 1 day share price return of 3.63%, a 90 day share price return of 29.65%, and a 1 year total shareholder return of 68.29%. These...